SCHEMBL3437015

SCHEMBL3437015

CC(C)OP(=O)(OC(C)C)C(F)P(=O)(OC(C)C)OC(C)C

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSA P10619 1/20 0.52
ACHE P22303 1/20 0.52
ALDH1A1 P00352 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
GAA P10253 1/20 0.34
ATM Q13315 1/20 0.34
POLB P06746 2/20 0.34
HMGCR P04035 4/20 0.33
MAPT P10636 1/20 0.33
KDM4E B2RXH2 1/20 0.33
CYP2C9 P11712 2/20 0.32
CYP2C19 P33261 2/20 0.32
KMT2A Q03164 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
CYP1A2 P05177 1/20 0.32
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19792821 0.87 CTSA (0.46) CTSAACHEALDH1A1L3MBTL1GAA
SCHEMBL15110959 0.82 CTSA (0.52) CTSAACHEALDH1A1L3MBTL1GAA
SCHEMBL6014466 0.77 CTSA (0.46) CTSAACHEALDH1A1L3MBTL1GAA
SCHEMBL575230 0.75 CTSA (0.50) CTSAACHEALDH1A1L3MBTL1GAA
SCHEMBL10910619 0.75 CTSA (0.50) CTSAACHEALDH1A1L3MBTL1GAA
SCHEMBL7163625 0.73 CTSA (0.48) CTSAACHEALDH1A1L3MBTL1GAA
SCHEMBL1459532 0.72 CTSA (0.48) CTSAACHEALDH1A1L3MBTL1GAA
SCHEMBL10991639 0.71 CTSA (0.46) CTSAACHEALDH1A1L3MBTL1GAA
SCHEMBL10832923 0.71 CTSA (0.46) CTSAACHEALDH1A1L3MBTL1GAA
SCHEMBL7160098 0.71 CTSA (0.46) CTSAACHEALDH1A1L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994304-B2 Sequencing nucleic acid molecules; promote accurate base-over-base incorporation in sequencing-by-synthesis reactions, resulting in greater read lengths HELICOS BIOSCIENCES CORPORATION (US) 2011-08-09 US disclosed
US-7807653-B2 Nucleotide mimics and their prodrugs BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2010-10-05 US disclosed
US-7598230-B2 For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2009-10-06 US disclosed
US-20080227970-A1 Methods And Compositions For Sequencing A Nucleic Acid HELICOS BIOSCIENCES CORPORATION (US) 2008-09-18 US disclosed
US-20070265224-A1 Nucleotide mimics and their prodrugs BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2007-11-15 US disclosed
US-20070259832-A1 Nucleotide mimics and their prodrugs BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2007-11-08 US disclosed
US-7285658-B2 Nucleotide mimics and their prodrugs BIOTA, INC. (US) 2007-10-23 US disclosed
EP-1485395-A2 NUCLEOTIDE MIMICS AND THEIR PRODRUGS Biota, Inc. (US) 2004-12-15 EP disclosed
WO-2003072757-A9 NUCLEOTIDE MIMICS AND THEIR PRODRUGS BIOTA INC (US) 2004-10-21 WO disclosed
US-20040059104-A1 Nucleotide mimics and their prodrugs BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2004-03-25 US disclosed
WO-2003072757-A2 NUCLEOTIDE MIMICS AND THEIR PRODRUGS BIOTA, INC. (US) 2003-09-04 WO disclosed
US-6255518-B1 Preparation of fluorinated compounds F2 CHEMICALS, LIMITED (GB) 2001-07-03 US disclosed
EP-1001918-A1 PREPARATION OF FLUORINATED COMPOUNDS F2 Chemicals Limited (GB) 2000-05-24 EP disclosed
WO-1999005080-A1 PREPARATION OF FLUORINATED COMPOUNDS F2 CHEMICALS LIMITED (GB) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259832-A1 Nucleotide mimics and their prodrugs NUDT14, ENTPD5, MTAP CTSA 3474/4885ACHE 3755/4885ALDH1A1 2112/4885
US-20070265224-A1 Nucleotide mimics and their prodrugs NUDT14, ENTPD5, MTAP CTSA 3474/4885ACHE 3755/4885ALDH1A1 2112/4885
US-20080227970-A1 Methods And Compositions For Sequencing A Nucleic Acid RNGTT, NT5C3B, POLN CTSA 4719/4885ACHE 4871/4885ALDH1A1 4557/4885
US-20040059104-A1 Nucleotide mimics and their prodrugs NUDT14, ENTPD5, MTAP CTSA 3474/4885ACHE 3755/4885ALDH1A1 2112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.